Company
Headquarters: Heze, China
Employees: 8,191
CN¥16.21 Billion
CNY as of Jan. 1, 2025
US$2.22 Billion
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Shandong Buchang Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of medicines in China. It offers medicines to treat cardiac and cerebral vascular, urinary and digestive, respiratory, gynecological, and other diseases, as well as diabetes. The company was founded in 1993 and is based in Heze, China. Shandong Buchang Pharmaceuticals Co., Ltd. was a former subsidiary of Shanghai Zhangjiang (Group) Co., Ltd.
| Last Financial Reports Date | Sept. 30, 2024 |
| Revenue TTM | CN¥11.78 B |
| EBITDA | CN¥676.4 M |
| Gross Profit TTM | CN¥6.93 B |
| Profit Margin | -2.49% |
| Operating Margin | 8.36% |
| Quarterly Revenue Growth | 1.90% |
Shandong Buchang Pharmaceuticals Co. Ltd has the following listings and related stock indices.
Stock: SSE: 603858 wb_incandescent